Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma
Maaike E. Ressing(Utrecht University), Cornelis J.M. Melief(ISA Pharmaceuticals (Netherlands)), Jan W. Drijfhout(Leiden University), Geziena M. Th. Schreuder(Leiden University Medical Center), W. Martin Kast(University of Southern California), Willemien E. Benckhuijsen(Leiden University), Rienk Offringa(German Cancer Research Center), Joan H. de Jong(Leiden University), Remco M.P. Brandt(Leiden University)
European Journal of Immunology
April 1, 1999
Cited by 50
Related Papers
Therapeutic cancer vaccines
|Journal of Clinical Investigation|2015|1.1k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells
|Nature Medicine|2002|549